Drugmakers have increasingly been pursuing the accelerated approval route after 2010, but the regulatory pathway has nonetheless been subject to a fresh wave of criticism from researchers, with the Journal of the American Medical Association (JAMA) most recently raising concerns.
In an Aug. 15 article, the London School of Economics and Political Science's Huseyin Naci and Katelyn Smalley and Harvard...







